Author

O. I. Kalbus

Observed names: O. Kalbus, O.I. KALBUS, O.I. Kalbus, O. I. Kalbus, Oleksandr Kalbus, Olexandr I. Kalbus, Кальбус А.И., О І Кальбус, О. І. Кальбус, Олександр Кальбус

Institution: Dnipro State Medical University

Observed institutions: University of London, Inserm, Queen Mary University of London, University of Basel, Ukrainian Medical Stomatological Academy, Université de Lille, University of Michigan, University Hospital of Basel, Centre Hospitalier Universitaire de Lille, Lille Neurosciences & Cognition, Dnipro State Medical University

ORCID: 0000-0003-0796-4825

Observed ORCID: 0000-0003-0796-4825

OpenAlex ID: A5085023541

Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial

2021 · Daniel S Reich, Douglas L Arnold, et al. · The Lancet Neurology · 214

PDF

Inhibition of CD40L with Frexalimab in Multiple Sclerosis

2024 · Patrick Vermersch, Cristina Granziera, et al. · New England Journal of Medicine · 115

PDF

Clinical and Immunological Comparisons in Patients with Myasthenia Gravis

2018 · O. I. Kalbus · Ukraïnsʹkij žurnal medicini bìologìï ta sportu · 8

PDF

Assessment of quality of life in patients with myasthenia

2018 · Oleksandr Kalbus · ScienceRise Medical Science · 7

PDF

Study the quality of life and anxiety in patients with myasthenia (clinical-parachlinal comparison)

2018 · Oleksandr Kalbus · ScienceRise Medical Science · 6

PDF

Methodological Aspects of Teaching the Cycle "Neurology" to Foreign Students at Dnipro State Medical University

2022 · I. O. Filiuk, O. I. Kalbus, et al. · Ukraïnsʹkij žurnal medicini bìologìï ta sportu · 4

PDF

151. Safety and Efficacy of Frexalimab in the Treatment of Relapsing Multiple Sclerosis: 18-month Results from the Phase 2 Open-Label Extension

2024 · Gavin Giovannoni, Cristina Granziera, et al. · Multiple Sclerosis and Related Disorders · 2

Цифрові Інструменти В Сучасній Вищій Медичній Освіті: Перспективи Та Виклики У Ххі Столітті

2024 · Олександр Кальбус, Наталя Шастун, et al. · Перспективи та інновації науки · 2

PDF

Anxiety and depression in patients with multiple sclerosis

2023 · O.V. Somilo, S.O. Makarov, et al. · Medicni perspektivi · 2

PDF

Features of depression development in myasthenia gravis.

2020 · O. I. Kalbus, S. O. Makarov, et al. · Medicni perspektivi · 2

PDF

Advantages of the Case-based Learning in Medical Education

2020 · S. O. Makarov, O. I. Kalbus, et al. · Bulletin of Problems Biology and Medicine · 2

Management of Exacerbations and Rescue Therapy in the Phase 3 Myasthenia Gravis Inebilizumab Trial: A Prespecified Analysis of a Randomized Clinical Trial

2026 · Richard J. Nowak, Kimiaki Utsugisawa, et al. · JAMA Neurology · 1

PDF

Integration of Assessment Scales for the Diagnosis of Chronic Migraine and Tension-type Headache

2025 · Yuliia V. Bukreieva, Olexandr I. Kalbus, et al. · Clinical and Preventive Medicine · 1

PDF

Multiple sclerosis: peculiarities of providing high-quality medical care to patients in the realities of Ukraine

2025 · T.I. Nehrych, N.P. Voloshyna, et al. · INTERNATIONAL NEUROLOGICAL JOURNAL · 1

PDF

Розвиток Медичних Навичок Через Мультидисциплінарний Підхід: Впровадження Steam-освіти

2024 · Олександр Кальбус, Тетяна Юдіна, et al. · Наука і техніка сьогодні · 1

PDF

Diagnostic Value of the Luria 10-word Memorization Technique and Schulte Tables in the Diagnosis of Mild Cognitive Dysfunction in Patients With Multiple Sclerosis

2024 · D. I. Andreichenko, O. I. Kalbus · Bulletin of Problems Biology and Medicine · 1

PDF

Prognosis of Disability in Relapsing-remitting Multiple Sclerosis

2023 · O. V. Somilo, O. I. Kalbus, et al. · World of Medicine and Biology · 1

The Role of Antibodies to Acetylcholine, Muscle-specific Kinase, Titin and Sox1 Receptors in Predicting Severe Myasthenia Gravis

2022 · O. I. Kalbus, O. O. Nefodov · World of Medicine and Biology · 1

Computer Simulation of the Combined Use of Azathioprine With Methylprednisolone Under the Conditions of Pharmacotherapy of Myasthenia Gravis

2022 · V. B. Larionov, O. O. Nefodov, et al. · World of Medicine and Biology · 1

The evaluation of approaches to the treatment of myasthenia gravis.

2019 · O. I. Kalbus, N. P. Shastun, et al. · Medicni perspektivi · 1

PDF

Safety and Efficacy of Frexalimab in Participants With Relapsing Multiple Sclerosis: 2.5-Year Results From the Phase 2 Open-label Extension

2026 · Patrick Vermersch, Cristina Granziera, et al. · Multiple Sclerosis and Related Disorders

Myalgic encephalomyelitis/chronic fatigue syndrome: current state of the problem (review article)

2026 · L.A. Dzyak, O.I. Kalbus, et al. · Medicni perspektivi

PDF

Efficacy and Safety of Frexalimab in Participants With Relapsing Multiple Sclerosis: 3-Year Results From the Phase 2 Open-label Extension (P7-19.003)

2026 · Patrick Vermersch, Stephen Krieger, et al. · Neurology

Comparative Efficacy of Transfusion Strategies in Women and Men With Myocardial Infarction and Anemia: Prespecified Secondary Findings From the MINT Trial

2026 · J. Dawn Abbott, Jocelyne R. Benatar, et al. · Circulation

Étude de phase 2 dans la SEP rémittente (SEP-R) évaluant l’efficacité et la sécurité d’emploi de Frexalimab (FREX) : données à 2,5 ans (120 semaines) de la période d’extension en ouvert

2026 · Patrick Vermersch, Cristina Granziera, et al. · Revue Neurologique

Works count: 77

Citation count: 373

H-index: 5

I10-index: 2